NASDAQ:ZNTL Zentalis Pharmaceuticals Q3 2024 Earnings Report $3.70 +0.14 (+3.93%) Closing price 08/17/2026 04:00 PM EasternExtended Trading$3.78 +0.07 (+2.03%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Zentalis Pharmaceuticals EPS ResultsActual EPS-$0.56Consensus EPS -$0.92Beat/MissBeat by +$0.36One Year Ago EPSN/AZentalis Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AZentalis Pharmaceuticals Announcement DetailsQuarterQ3 2024Date11/12/2024TimeAfter Market ClosesConference Call DateTuesday, November 12, 2024Conference Call Time9:30AM ETConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Zentalis Pharmaceuticals Earnings HeadlinesZentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesAugust 17 at 7:21 PM | markets.businessinsider.comZentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional SharesAugust 17 at 4:01 PM | globenewswire.comDid you see the WSJ on 8-9?On August 9, the Wall Street Journal profiled a unique AI strategy used by three companies. Whitney Tilson of Stansberry Research says one of them has returned more than Apple, Amazon, and the S&P 500 index combined in recent years. One well-known Wall Street money manager reportedly has roughly half his entire fund in this stock. Tilson's free write-up names the company and ticker, with no subscription required. | Stansberry Research (Ad)Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Recommendation of "Hold" by AnalystsAugust 16 at 2:28 AM | americanbankingnews.comZentalis Pharmaceuticals Prices $80.5 Million Offering to Fund Clinical PipelineAugust 14, 2026 | finance.yahoo.comZentalis Pharmaceuticals slides after pricing 23M share public offering at $3.50/shareAugust 14, 2026 | msn.comSee More Zentalis Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Zentalis Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zentalis Pharmaceuticals and other key companies, straight to your email. Email Address About Zentalis PharmaceuticalsZentalis Pharmaceuticals (NASDAQ:ZNTL) is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies. The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers. In addition to ZN-c3, Zentalis’ pipeline includes programs targeting Polo-like kinase 1 (PLK1) and other novel oncogenic pathways. Preclinical studies conducted by the company have demonstrated promising activity across multiple tumor models, supporting further advancement of these candidates into human trials. Zentalis applies an integrated discovery and development model, combining computational chemistry, structural biology and in-house medicinal chemistry to accelerate the identification of potent and selective drug candidates. The company collaborates with leading contract research organizations and academic institutions to support its preclinical and clinical research programs, with the goal of streamlining the path from discovery through clinical proof-of-concept. Founded in 2017 and headquartered in New Haven, Connecticut, Zentalis Pharmaceuticals completed its initial public offering in 2020. The company is led by President and Chief Executive Officer Robert Farrell, Ph.D., whose experience in oncology drug discovery guides the organization’s strategic direction. Zentalis continues to advance its oncology pipeline with the aim of bringing novel treatment options to patients worldwide.View Zentalis Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Birkenstock Beats the Skeptics—But Not on EPSThese 5 Dividend Stocks Show Why Income Investing Still MattersThe Quantum Race Is Heating Up—And 2 Small Players Stand OutMarketBeat Week in Review – 08/10 - 08/14Applied Materials Beat Everything but Wall Street’s Expectations for MarginsLooking Beyond CrowdStrike? 3 AI Security Stocks Stand Out5 Recession-Proof Stocks Hiding in Cardboard Boxes Upcoming Earnings Lowe's Companies (8/19/2026)TJX Companies (8/19/2026)Target (8/19/2026)Analog Devices (8/19/2026)NetEase (8/20/2026)Alibaba Group (8/20/2026)Ross Stores (8/20/2026)Walmart (8/20/2026)Deere & Company (8/20/2026)PDD (8/24/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
